We identified that patients with primary breast tumors with high phosphorylation of ER-α Ser167, or high expression of PRA or PRB, significantly responded to endocrine therapy, whereas phosphorylation of ER-α Ser118 and expression of ER-β1 and ER-βcx/β2 did not influence response. The gene discussed is S100A6; the disease is breast neoplasm.